2009 Fiscal Year Final Research Report
Establishment of newly cancer therapy for expression of target molecules with cancer stem cells in ovarian carcinoma
| Project/Area Number |
19591942
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Obstetrics and gynecology
|
|---|
| Research Institution | Dokkyo Medical University |
|---|
Principal Investigator |
YASUDA Shin-ichi Dokkyo Medical University, 医学部, 主任 (60133279)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
INABA Noriyuki 獨協医科大学, 医学部, 教授 (70114238)
FUKASAWA Ichio 獨協医科大学, 医学部, 教授 (00189911)
|
|---|
| Project Period (FY) |
2007 – 2009
|
| Keywords | 腫瘍幹細胞 / ヒト卵巣癌 / 分子治療標的 / マイクロRNA / 明細胞腺癌 |
|---|
| Research Abstract |
We assumed that we can obtain favorable therapy results by establishing a new selective cancer therapy through analyzing an expressed molecular to ovarian cancer stem cells, selecting more specific molecular to ovarian cancer stem cells, and use them as a marker for the therapy. Firstly, In cell cycle GO phase, we detected three genes ; ABCG2 which relate to anticancer drug efflux, FOXO3a that is a GO phase suppressor gene and specific expression of ubiquitin ligases subunites F bw7. We also detected high expression of microRNA for regulating ABCG2 gene in GO cells. Whereas, By side population (SP) method, we detected the cancer stem cell in clear cell ademocarcinoma which include high frequency SP cells. Since these cells showed adipocytes-like character similar to a clinical picture and PPARγ that specific gene to adipocytes was highly expressed, an anticancer drug does not effect well and maintain of cell undifferentiation. We detected similar genes at malcroarray.
|
